Skip to main content
SpringerLink
Log in

Systemic therapy with single agents for advanced or recurrent endometrial carcinoma

  • Chapter
Endometrial Cancer

Part of the book series: Cancer Treatment and Reasearch ((CTAR,volume 49))

Abstract

Endometrial carcinoma, now the most common invasive lesion of the female genital tract with over 40,000 cases annually, is regarded as a curable malignancy for several reasons: (1) symptoms in the form of abnormal bleeding occur early in the disease course, (2) the process at diagnosis is usually confined to the corpus of the uterus, (3) a majority of such lesions are well differentiated, and (4) the resultant cure rate from surgery alone is better than 90%. Despite this evidence of success, overall survival figures show that one-third of all patients with endometrial carcinoma recur within five years of diagnosis; most of these die from the malignancy. Until thirteen years ago, no major effort had sought effective systemic therapy for these unfortunate individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. De Vita VT,Jr, Wasserman T, Young RC, et al., 1976. Perspectives and research in gynecologic oncology. Cancer 38:509–525.

    Article  Google Scholar 

  2. Kelley RM, Baker WH, 1960. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264:216–222.

    Article  Google Scholar 

  3. Kohorn E, 1976. Gestagens and endometrial carcinoma. Gynecol Oncol 4:398–411.

    Article  PubMed  CAS  Google Scholar 

  4. Bonte J, DeCostu JM, Ide P, et al., 1978. Hormonoprophylaxis andhormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 6:60–75.

    Article  PubMed  CAS  Google Scholar 

  5. Sail S, DiSaia PJ, Morrow CP, Mortel R, Prem K, Thigpen JT, Creasman WT, 1979. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Amer J Obstet Gynecol 135:647–650.

    Google Scholar 

  6. Thigpen JT. Personal communication.

    Google Scholar 

  7. Piver S, Barlow J, Lurain J, et al., 1980. Medroxyprogesterone acetate (Depo-provera) vs hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45:268–272.

    Article  PubMed  CAS  Google Scholar 

  8. Billiet G, DeHertogh R, Bonte J, et al., 1982. Estrogen receptors in human uterine adenocarcinoma: Correlation with tissue differentiation, vaginal karyopycnotic index, and effect of progestogen on anti-estrogen treatment. Gynecol Oncol 14:33.

    Article  PubMed  CAS  Google Scholar 

  9. Creasman WT, McCarty K,Sr, Barton T, et al., 1980. Clinical correlates of estrogen and progesterone binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55:363–370.

    PubMed  CAS  Google Scholar 

  10. Ehrlich CE, Young P, Cleary R, 1981. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications. Amer J Obstet Gynecol 141:539–546.

    CAS  Google Scholar 

  11. Benraad T, Finberg L, Koenders A, et al., 1980. Do estrogen and progesterone receptors in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand 59:155–159.

    Article  PubMed  CAS  Google Scholar 

  12. Martin P, Rolland P, Ganxamerre M, et al., 1979, Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlation between receptors, histopathologic examinations, and clinical responses under progestin therapy. Int J Cancer 23:321–329.

    Article  PubMed  CAS  Google Scholar 

  13. McCarty L,Jr, Barton T, Fetter B, et al., 1979. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Amer J Pathol 96:171–182.

    Google Scholar 

  14. Jordan VC, 1976. The anti-tumor effect of tamoxifen in the dimethylbenzanthracene-induced rat mammary carcinoma model. In Proceedings of a Symposium on Hormonal Control of Breast Cancer. Alderly Park, Sept 24, pp. 11–17.

    Google Scholar 

  15. Hahnel R, Twaddle E, Ratajczak t, 1973. The influence of synthetic antiestrogens on the binding of tritiated estradio-17 beta by cytosols of human uterus and human breast carcinoma. J Steroid Biochem 4:687.

    Article  PubMed  CAS  Google Scholar 

  16. Lippman M, Bolan G, Huff K, 1976. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595–4601.

    PubMed  CAS  Google Scholar 

  17. Swenerton K, 1980. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64:805.

    PubMed  CAS  Google Scholar 

  18. Bonte J, Ide P, Billiet G, et al., 1981. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol 11:140.

    Article  PubMed  CAS  Google Scholar 

  19. Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley HD, 1984. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 68:809–811.

    PubMed  CAS  Google Scholar 

  20. DiMarco A, Zunino F, Silvestrini R, Gambarucci C, Gambetto RA, 1971. Interaction of some daunomvrin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol 20:1323–1328.

    Article  CAS  Google Scholar 

  21. Kim SH, Kim JH, 1972. Lethal effect of adriamycin on Hela cells. Caner Res 32:323–325.

    CAS  Google Scholar 

  22. Benjamin RS, 1975. Clinical pharmacology of adriamycin (NSC-123127). Cancer Chemother Rep, Part 3, 6:183–185.

    Google Scholar 

  23. Thigpen T, Buchsbaum, Mangan C, Blessing JA, 1979. Phase II trial of adriamycin in the treatment of advanced of recurrent endometrial carcinoma. Cancer Treat Rep 63:21–27.

    PubMed  CAS  Google Scholar 

  24. Horton J, Bezz C, Arseneau J, et al., 1978. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62:159–161.

    PubMed  CAS  Google Scholar 

  25. Thigpen JT. Personal communication.

    Google Scholar 

  26. Roberts JJ, Pascoe JM, 1872. Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (London) 235:282–284.

    Article  Google Scholar 

  27. DeConti RC, Toftness BR, Lange RC, et al., 1973. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33:1310–1315.

    PubMed  CAS  Google Scholar 

  28. Thigpen T, Blessing J, Lagasse L, DiSaia P, Homesley H, 1984. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. Amer J Clin Oncol 7:253–256.

    Article  CAS  Google Scholar 

  29. Seski J, Edwards C, Herson J, et al., 1982. Cisplatin chemotherapy for disseminted endometrial cancer. Obstet Gynecol 59:225–228.

    PubMed  CAS  Google Scholar 

  30. Trope C, Grundsell H, Johnson J, et al., 1980. A phase II study of cisplatinum for recurrent corpus cancer. Eur J Cancer 16:1025–1026.

    PubMed  CAS  Google Scholar 

  31. Deppe G, Cohen, C, Bruckner H, 1980. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammineplatinum (II) after intensive prior therapy. Gynecol Oncol 10:51–54.

    Article  PubMed  CAS  Google Scholar 

  32. Thigpen JT. Personal communication.

    Google Scholar 

  33. Wiltshaw E, Evans B, Harland S, 1985. Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV. Proc Amer Soc Clin Oncol 4:121.

    Google Scholar 

  34. Pecorelli S, Bolis G, Vassena L, Epis A, Landoni F, Zanaboni F, Vergadoro F, Favalli G, Gambino A, Marsoni S, Torri W, Jannsen N, Mangioni C, 1988. Randomized comparison of cisplatin (P) and carboplatin (C) in advanced ovarian cancer. Proc Amer Soc Clin Oncol 7:136.

    Google Scholar 

  35. McGuire WP, Arseneau J, Blessing J, Given F, Hatch K, Creasman W, DiSaia P, Teng N, 1988. Randomized comparison of carboplation (CP) and iproplatin (IP) in advanced squamous carcinoma of the uterine cervix (SCUC): A Gynecologic Oncology Group (GOG) study. Proc Amer Soc Clin Oncol 7:135.

    Google Scholar 

  36. Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmondson JH, Buckner JC, 1988. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Instit 80:276–278.

    Article  CAS  Google Scholar 

  37. Alberts D. Personal communication.

    Google Scholar 

  38. Seski J, Edwards C, Copeland L, et al., 1981. Hexamethylmelamine chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58:361–363.

    PubMed  CAS  Google Scholar 

  39. Thigpen JT. Personal communication.

    Google Scholar 

  40. Thigpen JT. Personal communication.

    Google Scholar 

  41. Slayton R. Personal communication.

    Google Scholar 

  42. Salyton R, Faraggi D, 1986. A phase II clinical trial of methyl-glyoxal-bis-guanylhydra-zone (MGBG) in advanced endometrial cancer. Proc Amer Soc Clin Oncol 5:119, 1986.

    Google Scholar 

  43. Omura G, Shingleton H, Creasman W, Blessing J, Bornow R, 1978. Chemotherapy of gynecologic cancer with nitrosoureas: A randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina, and vulva. Cancer Treat Rep 62:833–835.

    PubMed  CAS  Google Scholar 

  44. Levin L, Hryniuk W, 1987. The use of dose intensity (DI) analysis to solve problems in gynecologic oncology. Proc Amer Soc Clin Oncol 6:119.

    Google Scholar 

  45. Thigpen T, Blessing J, Homesley H, Petty W, 1986. Phase II trial of piperazinedione in treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Amer J Clin Oncol 9:21–23.

    Article  CAS  Google Scholar 

  46. Slayton R, Blessing J, Delgado G, 1982. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep 66:1669–1671.

    PubMed  CAS  Google Scholar 

  47. Stehman F, Blessing J, Delgado G, Louka M, 1983. Phase II evaluation of dianhydrogalac-titol in the treatment of advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 67:737–738.

    PubMed  CAS  Google Scholar 

  48. Homesley H, Blessing J, Conroy J, Hatch K, DiSaia P, Twiggs L, 1986. ICRF-159 (Razoxane) in patients with advanced adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Am J Clin Oncol 9:15–17.

    Article  PubMed  CAS  Google Scholar 

  49. Muss H, Bundy B, DiSaia P, Ehrlich C, 1987. Mitoxantrone for carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 71:217–218.

    PubMed  CAS  Google Scholar 

  50. Asbury R. Personal communication.

    Google Scholar 

  51. Muss H. Personal communication.

    Google Scholar 

Download references

Authors
  1. Tate Thigpen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Southern Arizona Surgical Oncology, Ltd, 85712, Tucson, Arizona, USA

    Earl A. Surwit M.D.

  2. College of Medicine, University of Arizona, 85124, Tucson, Arizona, USA

    David S. Alberts M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Thigpen, T. (1989). Systemic therapy with single agents for advanced or recurrent endometrial carcinoma. In: Surwit, E.A., Alberts, D.S. (eds) Endometrial Cancer. Cancer Treatment and Reasearch, vol 49. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0867-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0867-6_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8210-5

  • Online ISBN: 978-1-4613-0867-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation